ASH 2023 | Luspatercept in patients with HbE/β‑thalassemia: a subgroup analysis from the BELIEVE study
Kevin Kuo, MD, MSc, FRCPC, University Health Network, Toronto, Canada, discusses a post hoc subgroup analysis from the BELIEVE trial (NCT02604433), which evaluated the efficacy and safety of longer-term luspatercept treatment in patients with hemoglobin E (HbE)/β-thalassemia. The response rate in these patients was consistent with that of the larger study population, while the median total duration of response was longer in this subgroup. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Agios Pharmaceuticals, Alexion Pharmaceuticals, Bristol Myers Squibb, Forma Therapeutics, Pfizer, Novo/Nordisk, Vertex Pharmaceuticals
Research Funding: Agios Pharmaceuticals
Honoraria: Bristol Myers Squibb, Novo/Nordisk
Board of Directors/Advisory Committee: Bioverativ, Sanofi, Sangamo
